Explore the words cloud of the ONCO-VAX project. It provides you a very rough idea of what is the project "ONCO-VAX" about.
The following table provides information about the project.
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
|Coordinator Country||Germany [DE]|
|Total cost||1˙499˙988 €|
|EC max contribution||1˙499˙988 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2020-04-01 to 2025-03-31|
Take a look of project's partnership.
|1||KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN||DE (MUENCHEN)||coordinator||1˙499˙988.00|
Despite many decades of intensive research, cancer remains a major worldwide health concern and imposes a heavy societal burden, both epidemiologically and financially. Cancer immunotherapy is rapidly transforming the face of medical oncology as an exciting paradigm shift in treating cancer by exploiting the immune system of the patient as the basis for the therapy. Although dramatic results have been achieved in a subset of patients, the responses in most solid tumors have been disappointing. Hepatocellular carcinoma (HCC) represents a particularly challenging malignancy to treat, due to the inherently immune-suppressive microenvironment in the liver. Oncolytic viruses (OVs) offer an elegant multimodal approach to combat HCC through their ability to cause direct tumor cell lysis, while stimulating immune responses directed against the tumor. Nevertheless, the potential of OVs as monotherapeutics is limited by the innate antiviral immune response, which rapidly restricts virus replication and spread within the tumor mass. Therefore, a successful therapeutic strategy should employ a combination scheme involving a mechanism to improve the intratumoral dissemination of the OV, while exploiting the immune-stimulatory capacity of the virus, in order to achieve far-reaching synergistic responses that can target metastatic disease. The ONCO-VAX approach aims to accomplish just that. A novel chimeric oncolytic virus backbone with an enhanced cell-cell spreading capacity, will be utilized as a platform to express an optimized gene for eradicating the local immune-suppressive microenvironment in the tumor. As an additional layer of therapy, the virus will be combined with a cutting edge dendritic cell vaccine approach to initiate a broad antitumor response for systemic and potentially life-long immunity against the cancer. This multifaceted approach represents an innovative and crucial step forward in the rapidly evolving field of cancer immuno-oncology.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCO-VAX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ONCO-VAX" are provided by the European Opendata Portal: CORDIS opendata.